RecruitingPhase 2Phase 3NCT06752616

Acute Agitation in Emergency Psychiatry

Advancing the Quality of Treatment and Care for Acute Agitation in Emergency Psychiatry


Sponsor

Lone Baandrup

Enrollment

132 participants

Start Date

Dec 30, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

The purpose of the study is to improve the pharmacological treatment of psychiatric patients with acute agitation.


Eligibility

Min Age: 18 YearsMax Age: 64 Years

Inclusion Criteria5

  • -64 years
  • Agitation with the need for tranquillization in inpatient psychiatric settings including psychiatric emergency rooms
  • Total score of ≥14 on the PANSS Excited Component (PEC)
  • A score ≥4 on at least 1 of the 5 items of the PEC
  • Informed consent obtained prior to the occurrence of the emergency

Exclusion Criteria11

  • Involuntary psychiatric admission according to the Danish Mental Health Act
  • Female patients who are breastfeeding
  • Female patients aged <50 years and unable to perform a negative urine screen for pregnancy and not using safe contraceptives
  • Body weight <50 kg
  • Extreme obesity defined as estimated BMI≥ 40 kg/m2
  • Clinical situations where acute administration of an antipsychotic is preferred to treat acute agitation (in the opinion of the investigator)
  • The patient deemed unwilling or unable to cooperate with study procedures (in the opinion of the investigator)
  • Insufficient language skills that interfere with reading, writing, and providing written informed consent in Danish or other available languages (in the opinion of the investigator)
  • Clinical suspicion of contraindications for one of the treatment arms
  • Use of benzodiazepines, other sedatives, or antipsychotic drugs in addition to usual treatment (i.e., additional PN sedative prescriptions) in the 4 hours before study treatment
  • Known allergy to any of the study medications

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGSublingual Dexmedetomidine

Sublingual dexmedetomidine 180 mcg, possible second dose 90 mcg after 2 hrs

DRUGBuccal midazolam

Buccal midazolam 10 mg, possible second dose 10 mg after 2 hrs

DRUGOral lorazepam

Oral lorazepam 4 mg, possible second dose 4 mg after 2 hrs


Locations(1)

Mental Health Center Copenhagen, Bispebjerg

Copenhagen N, Denmark

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06752616


Related Trials